- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.01. | Viking enlists commercial chief to battle obesity giants, while Aspen names CCO to prep for Parkinson's launch | ||
| 07.01. | Lilly's prospective cardiometabolic launches dominate list of drugs to watch in 2026: Clarivate | ||
| 06.01. | Jazz touts Ziihera as the new HER2 agent of choice in stomach cancer | ||
| 06.01. | M+C Saatchi taps former Pfizer CMO Freda Lewis-Hall as 1st medical advisor | ||
| 06.01. | J&J's Tremfya outstrips AbbVie's Skyrizi again, closing out 2025 as December's top TV ad spender | ||
| 06.01. | 3 biopharma CEOs explain why they are 'authentically optimistic' for 2026 | ||
| 06.01. | AstraZeneca looks to grow reach in lupus with phase 3 win for self-administered Saphnelo | ||
| 05.01. | As Vyvgart empire expands, argenx CEO passes reins to operating chief Karen Massey | ||
| 05.01. | Bausch + Lomb brings glaucoma into focus with renewed awareness push | ||
| 05.01. | HCPs say pharmas' direct drug sale platforms have 'mixed' impact on GLP-1 access, care | ||
| 05.01. | Drugmakers raise prices of over 350 products, far outpacing last year: report | ||
| 05.01. | Daiichi Sankyo tallies $1.9B in planned Enhertu manufacturing investments: Nikkei | ||
| 05.01. | Novo's Wegovy pill makes US debut, with starter dose launching at $149 per month for cash-paying patients | ||
| 05.01. | Incyte to seek FDA approval for 7-drug Monjuvi regimen in 1st-line diffuse large B-cell lymphoma | ||
| 02.01. | Vanda's motion sickness drug, Agios' thalassemia treatment make the grade with FDA | ||
| 02.01. | Pacira brings Exparel DTC campaign to life with family-focused NYC event | ||
| 02.01. | Foresee Pharmaceuticals spots prostate cancer med's potential in rare puberty disease, touts phase 3 win | ||
| 02.01. | After scrapped trial, InflaRx could tap partner to revive development of COVID drug in rare skin disorder | ||
| 02.01. | Verastem nixes KRAS G12C plans in non-small cell lung cancer | ||
| 02.01. | Regulatory tracker: Outlook Therapeutics' ophthalmic bevacizumab hit with another FDA rejection | ||
| 29.12.25 | Acquisitive Sanofi keeps deals coming, laying out $2.2B for hepatitis vaccine maker Dynavax | ||
| 26.12.25 | Omeros scores its first-ever FDA nod as stem cell transplant drug Yartemlea approved | ||
| 23.12.25 | Baltimore jury orders J&J to pay $1.5B in largest-ever award to a talc plaintiff | ||
| 23.12.25 | Pfizer confirms patient death in Hympavzi hemophilia extension study | ||
| 23.12.25 | Neurocrine's Ingrezza fails phase 3 trial for cerebral palsy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .